Cat. No. | Product name | CAS No. |
DC7989 |
PEPA
Featured
PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity. |
141286-78-4 |
DC21021 |
Peptide P60
Featured
Peptide P60 (FOXP3 inhibitor P60) is a 15-mer synthetic peptide, cell-permeable inhibitor of FOXP3, binds specifically to FOXP3; inhibits murine and human-derived Treg and improves effector T cell stimulation, overcomes the inhibitory effect of FOXP3 on the activity of the transcription factors NF-κB and NFAT, inhibits upregulation of mRNA for Foxp3 and IL-10 on effector T cells and enhances mRNA for IFN-γ after anti-CD3 stimulation; induces a scurfy-like disease in newborn mice, improves vaccine efficacy in mice model of CT26 tumor and HCV infection. |
1319725-20-6 |
DCAPI1010 |
Peramivir Trihydrate
Featured
Peramivir, also known as BCX1812 and RWJ 270201, is an antiviral drug for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. Peramivir was approved to treat influenza infection in adults. |
1041434-82-5 |
DC7226 |
Perampanel(E2007)
Featured
Perampanel(E2007; ER 155055-90) is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials. |
380917-97-5 |
DC21821 |
Perhexiline maleate
Featured
Perhexiline maleate (WSM 3978G) is a prophylactic antianginal agent that inhibits carnitine palmitoyltransferase (CPT1/CPT2). |
6724-53-4 |
DC2021 |
Perifosine (KRX-0401)
Featured
Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM. |
157716-52-4 |
DC12059 |
Pertussis Toxin
Featured
Pertussis Toxin is a protein-based AB5-type exotoxin produced by the bacterium Bordetella pertussis, which causes whooping cough. |
70323-44-3 |
DC22930 |
PF-4878691 (3M-852A)
Featured
PF 04878691 (PF 4878691, S 32865, 852A, 3M 001) is a selective TLR7 agonist that potently induces IFN-α and IFN-regulated proteins from human PBMC. |
532959-63-0 |
DC10529 |
PF 05089771
Featured
PF 05089771 is a Nav1.7 channel blocker extracted from patent WO/2010/079443 A1, compound example 788, has an IC50 of 8.6 nM. |
1235403-62-9 |
DC10496 |
PF06260933
Featured
PF 06260933 is a potent and selective MAP4K4 inhibitor (IC50 value 3.7 nM for MAP4K4 a.k.a. HGK or ZC1) with suitable PK properties in mouse to be used as a tool in an in vivo model of diabetes, vascular inflammation and atherosclerosis. |
1811510-56-1 |
DC7691 |
PF 1022A
Featured
PF 1022A is a N-methylated cyclooctadepsipeptides (CODPs) with strong anthelmintic properties; acts as an ionophore. |
133413-70-4 |
DC8259 |
PF0477736
Featured
PF 477736 is a CHK inhitor with Ki values of 0.49 and 47 nM for Chk1 and Chk2 respectively. A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity |
952021-60-2 |
DC4106 |
PF573228
Featured
PF 573228 is a inhibitor of FAK with IC50 of 4 nM. |
869288-64-2 |
DC21477 |
PF 6260933 dihydrochloride
Featured
PF 6260933 is a potent, selective and orally bioavailable MAP4K4 inhibitor with kinase IC50 of 3.7 nM, cell IC50 of 160 nM. |
1883548-86-4 |
DC2086 |
PF-670462
Featured
PF 670462 is a selective casein kinase, CK1ε and CK1δ inhibitor which also shows potency against 42 other kinases. |
950912-80-8 |
DC20027 |
PF 750
Featured
PF 750 is a selective and covalent fatty acid amide hydrolase (FAAH) inhibitor, with IC50s varied from 16.2-595 nM in different pre-incubation times. Covalently modifies the enzyme’s active site serine nucleophile. |
959151-50-9 |
DC3168 |
PF-562271 PHSO3H SALT
Featured
PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
939791-38-5 |
DC10038 |
PF-01247324
Featured
PF-01247324 is an orally bioavailable, selective and potent NaV1.8 channel blocker that inhibits that exhibits analgesic efficacy in rodent behavioral models of pain. |
875051-72-2 |
DC8382 |
PF-03084014 (Nirogacestat)
Featured
PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2. |
1290543-63-3 |
DC21483 |
PF03715455
Featured
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2].PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6 and a potent inhibitor of CYP’s 2C9 and CYP3A4[2].PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively[2]. Animal Model: Male CD Sprague Dawley rats (300-450 g)[2] Dosage: 1 mg/kg Administration: I.v. (Pharmacokinetic Analysis) Result: The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively. |
1056164-52-3 |
DC7059 |
PF-03758309
Featured
PF-03758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. |
898044-15-0 |
DC24071 |
PF-04217903 methanesulfonate
Featured
PF-04217903 is a potent, selective, ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM, inhibits HGF-stimulated tyrosine phosphorylation of wild type c-Met with IC50 of 7.3 nM in cell-based assays. |
956906-93-7 |